Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis

Company Overview

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development. The lead program, D1-B701, is a selective FGFR4 inhibitor designed to treat FGF19-driven hepatocellular carcinoma and other solid tumors. Additional programs include D1-H201, a selective HDAC6 inhibitor for certain hematologic malignancies, and D1-R199, a RET kinase inhibitor targeting RET fusion-positive cancers. Each program is supported by companion diagnostic strategies aimed at enriching patient populations and optimizing clinical outcomes.

Founded in 2017, Day One Biopharmaceuticals is headquartered in San Diego, California, and maintains research and development operations in both the United States and Asia. The company’s leadership team comprises professionals with extensive experience in oncology drug discovery, clinical development, regulatory affairs and commercial strategy. Day One collaborates with academic and industry partners to advance its pipeline and remains committed to addressing significant unmet needs in cancer therapeutics through scientifically rigorous and patient-focused innovation.

Key Stats

• Today's Range: $21.49 to $21.53
• 50-Day Range: $10.03 to $21.53
• 52-Week Range: $5.64 to $21.53
• Volume: 2.99 million shs
• Average Volume: 1.52 million shs
• Market Capitalization: $2.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.83
• Consensus Rating: Reduce

Day One Biopharmaceuticals Stock Analysis - MarketRank™

Day One Biopharmaceuticals scored higher than 6% of companies evaluated by MarketBeat, and ranked 868th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Reduce

Consensus Rating

Day One Biopharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.89, and is based on no strong buy ratings, no buy ratings, 8 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Day One Biopharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Day One Biopharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Day One Biopharmaceuticals are expected to grow in the coming year, from ($0.86) to $0.01 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Day One Biopharmaceuticals is -20.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Day One Biopharmaceuticals is -20.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Day One Biopharmaceuticals has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DAWN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Day One Biopharmaceuticals does not currently pay a dividend.

Dividend Growth

Day One Biopharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

10 people have searched for DAWN on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Day One Biopharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.20% of the stock of Day One Biopharmaceuticals is held by insiders.

Percentage Held by Institutions

87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DAWN
• CIK: 1845337
• Web: dayonebio.com
• Phone: 650-484-0899
• Fax: N/A
• Employees: 60
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Day One Biopharmaceuticals: $22.83
• High Price Target: $34.00
• Low Price Target: $17.00
• Potential Upside/Downside: +6.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 2,153.00
• P/E Growth: N/A
• Net Income: -$107.32 million
• Net Margins: -67.85%
• Pretax Margin: -69.10%
• Return on Equity: -23.43%
• Return on Assets: -20.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.02
• Quick Ratio: 7.91

Sales & Book Value

• Annual Sales: $158.18 million
• Price / Sales: 14.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.30 per share
• Price / Book: 5.01

Miscellaneous

• Outstanding Shares: 103,330,000
• Free Float: 96,927,000
• Market Cap: $2.22 billion
• Optionable: Optionable
• Beta: -1.74